BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32676927)

  • 1. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
    Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
    Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
    [No Abstract]   [Full Text] [Related]  

  • 5. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
    Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [No Abstract]   [Full Text] [Related]  

  • 7. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer].
    Yamazaki H; Shimizu S; Iwasaki H; Yoshida T; Suganuma N; Yamanaka T; Kojima I; Masudo K; Toda S; Nakayama H; Masuda M
    Gan To Kagaku Ryoho; 2017 Aug; 44(8):695-697. PubMed ID: 28860443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
    Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
    Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.
    Kiyota N; Schlumberger M; Muro K; Ando Y; Takahashi S; Kawai Y; Wirth L; Robinson B; Sherman S; Suzuki T; Fujino K; Gupta A; Hayato S; Tahara M
    Cancer Sci; 2015 Dec; 106(12):1714-21. PubMed ID: 26426092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
    Higashiyama T; Sugino K; Hara H; Ito KI; Nakashima N; Onoda N; Tori M; Katoh H; Kiyota N; Ota I; Suganuma N; Hibi Y; Nemoto T; Takahashi S; Yane K; Ioji T; Kojima S; Kaneda H; Sugitani I; Tahara M
    Eur J Cancer; 2022 Sep; 173():210-218. PubMed ID: 35932627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
    Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
    Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cohort study exploring the effect of lenvatinib on differentiated thyroid cancer.
    Tahara M; Takami H; Ito Y; Sugino K; Takahashi S; Takeyama H; Tsutsui H; Hara H; Mitsuma A; Yamashita H; Okamoto T; Sugitani I; Ohashi Y; Imai T
    Endocr J; 2018 Nov; 65(11):1071-1074. PubMed ID: 30369531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States.
    Worden F; Rajkovic-Hooley O; Reynolds N; Milligan G; Zhang J
    Endocrine; 2024 May; 84(2):663-669. PubMed ID: 38102498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
    Kawamura Y; Saijo K; Imai H; Ishioka C
    Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
    Schlumberger M; Jarzab B; Cabanillas ME; Robinson B; Pacini F; Ball DW; McCaffrey J; Newbold K; Allison R; Martins RG; Licitra LF; Shah MH; Bodenner D; Elisei R; Burmeister L; Funahashi Y; Ren M; O'Brien JP; Sherman SI
    Clin Cancer Res; 2016 Jan; 22(1):44-53. PubMed ID: 26311725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Kiyota N; Hoff AO; Badiu C; Owonikoko TK; Dutcus CE; Suzuki T; Ren M; Wirth LJ
    Eur J Cancer; 2021 Apr; 147():51-57. PubMed ID: 33611104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
    Giani C; Valerio L; Bongiovanni A; Durante C; Grani G; Ibrahim T; Mariotti S; Massa M; Pani F; Pellegriti G; Porcelli T; Salvatore D; Tavarelli M; Torlontano M; Locati L; Molinaro E; Elisei R
    Thyroid; 2021 Feb; 31(2):224-232. PubMed ID: 32907501
    [No Abstract]   [Full Text] [Related]  

  • 20. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
    Sparano C; Godbert Y; Attard M; Do Cao C; Zerdoud S; Roudaut N; Joly C; Berdelou A; Hadoux J; Lamartina L; Schlumberger M; Leboulleux S
    Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.